Moffitt’s Blood Cancer Experts Share the Latest Research and Treatment Advances
Every three minutes, an American is diagnosed with leukemia, lymphoma or myeloma. It is an alarming statistic, but top hematologists from across the world are coming together to discuss the latest research and treatment advances to help those blood cancer patients have better outcomes. This week, more than 30,000 physicians and scientists gathered in New Orleans for the 64th Annual American Society of Hematology (ASH) Annual Meeting and Exposition.
Moffitt Cancer Center was well represented at the conference, presenting more than 55 abstracts on the latest research in the treatment of blood malignancies. Topics include identifying factors that can help predict patient outcomes to CAR T-cell therapy, how monoclonal antibody therapy for COVID can improve outcomes for stem cell transplant patients, and whether racial and ethnic differences impact outcomes in multiple myeloma. You can learn more about Moffitt’s presentations at the ASH annual meeting by visiting Moffitt.org/ASH and by reading the stories below.
Read Moffitt’s ASH 2022 Stories
Moffitt Investigates First-of-Its-Kind Cellular Therapy in MDS Patients
Novel approach uses mismatched donor lymphocytes to activate patient’s immune system
Donor CAR T May Increase Remission in Relapsed or Refractory AML Patients
Good clinical responses seen for using genetically modified product
New Therapy Shows Promise for Myelodysplastic Syndrome Patients
SX-682 works by targeting both adverse immune cells and cancer cells
Study Highlights Potential Disparities for CAR T Patients with Multiple Myeloma
Hispanics had lower response rates
